We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Elecsys Androstenedione Immunoassay Evaluated and Compared

By LabMedica International staff writers
Posted on 20 May 2022
Print article
Image: The new Elecsys Androstenedione assay has been compared and evaluated (Photo courtesy of Blood Tests London)
Image: The new Elecsys Androstenedione assay has been compared and evaluated (Photo courtesy of Blood Tests London)

Androstenedione (ASD) is a biomarker used in the diagnostic workup of hyperandrogenism, congenital adrenal hyperplasia, premature adrenarche, and polycystic ovary syndrome (PCOS). Androstenedione is the precursor of testosterone and estrone and is produced in the gonads and adrenal glands.

Along with other sex hormones, ASD is essential for the onset and development of sexual differentiation in males and females. ASD measurement in serum or plasma is used to assess adrenal and gonadal function and steroid hormone biosynthesis deficiency. A new ASD competitive electrochemiluminescence immunoassay has been evaluated.

Medical Laboratory Scientists at the Cleveland Clinic (Cleveland, OH, USA) evaluated the linearity/analytical measuring range (AMR), precision, and accuracy of the Elecsys ASD assay on the cobas e601 analyzer (Roche Diagnostics, Indianapolis, IN, USA). For comparison, the Immulite ASD was performed using the Immulite 2000 (Siemens Medical Solutions USA, Inc. Malvern, PA, USA). Specimens were sent to a reference laboratory for analysis by LC-MS/MS. The scientists used 40 specimens (33 sera and seven plasma samples) for the method comparison studies The Elecsys ASD assay is an 18-minute competitive electrochemiluminescence immunoassay that utilizes ASD-specific biotinylated monoclonal antibodies and ruthenium complex-conjugated ASD for ASD assessment.

The investigators reported that the Elecsys ASD assay had a linear response across the AMR. The intra- and inter-assay coefficients of variation at various concentrations were ≤4.5%. The Elecsys ASD assay had a mean difference of −0.04 ng/mL (−1.7%) with the LC-MS/MS assay, whereas the Immulite assay had a mean difference of 1.17 ng/mL (66%) and −1.22 ng/mL (−38%) compared to the LC-MS/MS and Elecsys ASD assays, respectively. The Roche recommended RIs for healthy men (0.280–1.52 ng/mL) and postmenopausal women (0.187–1.07 ng/mL) were successfully verified. The RIs for children were adopted from published data. For pre-menopausal women, a RI of <1.60 ng/mL was established. The ASD concentrations in women with and without PCOS overlapped.

The authors concluded that the Elecsys ASD assay has excellent precision, specificity, and accuracy. It offers many advantages over the Immulite ASD assay and is a suitable alternative for ASD measurement in clinical laboratories. However, the assay should be thoroughly validated before its use for clinical testing and reference intervals established for the patient population, as needed. The Elecsys ASD assay has superior comparability to the LC-MS/MS assay than the Immulite assay. The study was published on May 10, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Cleveland Clinic 
Roche Diagnostics 
Siemens Medical Solutions USA 

Platinum Supplier
Respiratory Virus Multiplex Test
Respiratory Virus 12 Types Nucleic Acid Detection Kit
Silver Supplier
SARS-CoV-2, Influenza A/B Test
RT-PCR Enzymes and Kits
QuantiNova Pathogen +IC Kit
Automatic Fecal Analyzer

Print article
IIR Middle East



view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.